BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18249537)

  • 1. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
    Wu Z; Hartnett JC; Neilson LA; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1274-9. PubMed ID: 18249537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid assembly of diverse and potent allosteric Akt inhibitors.
    Wu Z; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Kohl NE; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2211-4. PubMed ID: 18296048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
    Hartnett JC; Barnett SF; Bilodeau MT; Defeo-Jones D; Hartman GD; Huber HE; Jones RE; Kral AM; Robinson RG; Wu Z
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2194-7. PubMed ID: 18294842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
    Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
    Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
    Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D
    J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure based optimization of novel Akt inhibitors.
    Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
    Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors.
    Bencsik JR; Xiao D; Blake JF; Kallan NC; Mitchell IS; Spencer KL; Xu R; Gloor SL; Martinson M; Risom T; Woessner RD; Dizon F; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ; Prior WW; Murray LJ
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7037-41. PubMed ID: 20971641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
    Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
    Addie M; Ballard P; Buttar D; Crafter C; Currie G; Davies BR; Debreczeni J; Dry H; Dudley P; Greenwood R; Johnson PD; Kettle JG; Lane C; Lamont G; Leach A; Luke RW; Morris J; Ogilvie D; Page K; Pass M; Pearson S; Ruston L
    J Med Chem; 2013 Mar; 56(5):2059-73. PubMed ID: 23394218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents.
    Lukasik PM; Elabar S; Lam F; Shao H; Liu X; Abbas AY; Wang S
    Eur J Med Chem; 2012 Nov; 57():311-22. PubMed ID: 23085105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and SAR of spirochromane Akt inhibitors.
    Kallan NC; Spencer KL; Blake JF; Xu R; Heizer J; Bencsik JR; Mitchell IS; Gloor SL; Martinson M; Risom T; Gross SD; Morales TH; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2410-4. PubMed ID: 21392984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.
    Zhao Z; Robinson RG; Barnett SF; Defeo-Jones D; Jones RE; Hartman GD; Huber HE; Duggan ME; Lindsley CW
    Bioorg Med Chem Lett; 2008 Jan; 18(1):49-53. PubMed ID: 18054229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.
    Lücking U; Siemeister G; Schäfer M; Briem H; Krüger M; Lienau P; Jautelat R
    ChemMedChem; 2007 Jan; 2(1):63-77. PubMed ID: 17131463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
    Gopalsamy A; Ciszewski G; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 May; 19(10):2735-8. PubMed ID: 19362830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.
    Horiuchi T; Chiba J; Uoto K; Soga T
    Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
    Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.